Format

Send to

Choose Destination
J Infect Chemother. 2011 Dec;17(6):876-9. doi: 10.1007/s10156-011-0262-x. Epub 2011 Jun 11.

Clinical efficacy of arbekacin for Gram-negative bacteria.

Author information

1
Department of Pharmacy, Kitasato East University Hospital, 2-1-1, Asamizodai, Minami-ku, Sagamihara, Kanagawa 252-0380, Japan. yuki@kitasato-u.ac.jp

Erratum in

  • J Infect Chemother. 2011 Dec;17(6):880-1.

Abstract

In an analysis of methicillin-resistant Staphylococcus aureus (MRSA) infected patients treated with arbekacin (ABK) only, Gram-negative bacteria (GNB) that were inhibited by low minimal inhibitory concentrations (MICs) of amikacin (AMK) or gentamycin (GM) were eradicated by the end of the ABK treatment. On the other hand, GNB that were only inhibited by high MICs of AMK or GM persisted until the end of treatment with ABK only. Thus, ABK can be expected to be effective even in cases of mixed infection with GNB and MRSA.

PMID:
21667069
DOI:
10.1007/s10156-011-0262-x
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center